Back to results
US 2017/0291875 A1Published application
Quinolones as inhibitors of class iv bromodomain proteins
AssigneeUCL Business PLC
InventorsPaul Vincent Fish, Niall Igoe, Elliott David Bayle
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:
Claims27
A compound of general formula I:
- wherein:
- R3 is selected from —R3A and —OR3B wherein R3A and R3B are each independently selected from hydrogen, C1-4alkyl and C1-4haloalkyl;
- R4 is selected from —R4A and —OR4B wherein R4A and R4B are each independently selected from hydrogen, C1-4alkyl and C1-4haloalkyl;
- R5 is selected from —R5A and —OR5B wherein R5A is independently selected from hydrogen, halo, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-6cycloalkyl and C1-4haloalkyl, and wherein R5B is independently selected from hydrogen, C1-4alkyl, C3-6cycloalkyl and C1-4haloalkyl;
- R7 is selected from —R7A and —OR7B wherein R7A and R7B are each independently selected from hydrogen, C1-4alkyl, C3-6cycloalkyl, and C1-4haloalkyl;
- R8 is selected from —R8A and —OR8B wherein R8A is independently selected from hydrogen, halo, C1-4alkyl, and C1-4haloalkyl, and wherein R8B is independently selected from hydrogen, C1-4alkyl and C1-4haloalkyl;
- RN is selected from C1-4alkyl, C1-4haloalkyl, RZ, and —ZN—RZ wherein ZN is C1-4alkylene and each RZ is independently C3-6cycloalkyl;
- L is a sulfonamide linker;
- X is selected from aryl, C1-6alkyl and C3-6cycloalkyl and is optionally substituted.
6 more elements
23-26. (canceled)
Dependencies are inferred from the claim text.